Evonetix Ltd has completed yet another milestone in its pursuit of reimagining biology with proprietary DNA synthesis technologies. The company’s thermally controlled technology for DNA synthesis is now patented in Europe. This includes the design and manufacturing of its silicon chips. Evonetix has been relentlessly pursuing the development of a benchtop DNA synthesis platform. Such a platform is poised to change the way DNA is accessed, made and used. Thermally controlled synthesis is different from the conventional techniques and methods. The conventional synthesis techniques mostly utilize acid deprotection that doesn’t have the accuracy in comparison with the thermal techniques. The semiconductor-based arrays are deployed in the DNA synthesis controlled by the thermal platforms, equipping them to selectively deprotect sequences. This can aid in the removal of mismatching sequences while enabling the inclusion of the next nucleotide. This newly patented technology can now improve the access of DNA synthesis to the researchers. This will eventually change the way DNA is used in the research facilities with more precision and accuracy.
Emerging trends with Synthetic Biology
Synthetic Biology explores and exploits the possibility of engineering new biological systems for useful purposes. Developing new systems or redesigning the existing biological systems can extrapolate faster advancements in the area of Healthcare research and related segments. Building enhanced genetic engineering capabilities is one of the core purposes why researchers turn to synthetic biology techniques. Innovations in this area could positively lead to the invention and development of natural treatments or medical products. Practicing human medicine enabled by products designed through DNA synthesis may eventually become a compelling reality. This can drastically change or transform how the field of medicine is shaped for the future. Most of the techniques being studied under this discipline would require extensive validation and assurance before they are applied in outside-the-lab scenarios. However, the advancements in this area of research clearly indicate an exciting future with Healthcare innovations. Given this context, Evonetix’s patented technology holds significance in changing the research paradigms with improved speed and accuracy when it comes to the DNA assessment and analysis.
Evonetix Ltd – A pioneer in developing Next Generation DNA Synthesis platforms
The third-generation gene synthesis approach as highlighted by Evonetix has the potential of addressing multidisciplinary challenges that range across the fields of Healthcare, Agriculture, Materials Science, Industrial Biotechnology and Digital Data Storage. Such a disruptive approach of using genetic engineering technologies shall have an immense value with a measurable impact on drug discovery processes. Ambitious methods of gene editing and subsequent manufacturing of biological drugs can be powered by the synthetic platforms developed by Evonetix. Before securing its recent patent for the DNA synthesis technology, Evonetix was also rewarded another patent for its DNA data storage and retrieval method. It is certainly no surprise that Evonetix was named the “Life Science Company of the Year” at Cambridge Independent Science and Technology Awards last year in April.
